Tendyne Holdings, Inc., a privately held clinical stage medical device company, announced today that in November 2014 the Tendyne Transcatheter Mitral Valve Implantation system (TMVI) was successfully implanted in the first patient of the Tendyne Feasibility Study. This was the first patient enrolled in a three continent, multicenter trial, which aims to generate insight into the safety and performance of the Tendyne device in inoperable patients suffering from mitral regurgitation.
from The Medical News http://ift.tt/1sxnzlB
from The Medical News http://ift.tt/1sxnzlB
No comments:
Post a Comment